Company Profile. German-Taiwan Biotech Seminar 6 November 2017

Transcription

1 Company Profile German-Taiwan Biotech Seminar 6 November 2017

2 Our Mission Bayer: Science For A Better Life A growing and aging world population requires an adequate supply of food and improved medical care. Our research and development activities are therefore focused on improving people s quality of life by preventing, alleviating and treating diseases. At the same time, we are making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials. Our understanding of the biochemical processes in living organisms helps us address these demanding challenges. Folie 2 Bayer Company Profile 2017

3 Our Business Areas Pharmaceuticals Consumer Health Crop Science Prescription drugs Over-the-counter medicines, dietary supplements, dermatology products, foot care and sunscreen Innovative crop protection and seeds Animal Health Slide 3 Bayer Company Profile 2017

4 Employees* billion** Full year sales Subsidiaries billion*** R&D expenses Full year sales and R&D expenses: as of December 31, 2016 (excluding Covestro); Employees and Subsidiaries: as of September 30, 2017 (excluding Covestro) Slide 4 Bayer Company Profile 2017

5 Key Locations / Regions Europe / Middle East / Africa North America Asia / Pacific Latin America The Bayer Group is a global enterprise with companies in 91 countries. Folie 5 Bayer Company Profile 2017

6 Bayer Taiwan s 25th Anniversary Celebration in 2014 Bayer Taiwan Co., Ltd. In Taipei 101 Central Office in Taichung Southern Office in Kaohsiung Slide 6

7 Bayer Taiwan Co., Ltd. Slide 7

8 Bayer s Success is Based on Excellence in Research & Development Continuous Investment in R&D Projects Input Output Other 55 million Animal Health 140 million R&D staff: % 1 % 3 % R&D expenses 2016: 4.4 billion 63 % Pharmaceuticals 2,787 million R&D staff: 7,934 Pharmaceuticals Twelve new molecular entities transferred from research pipeline into preclinical development in 2016 Consumer Health 30 new products developed from new delivery forms and formulations Crop Science Crop Science 1,164 million R&D staff: 5,631 6 % Consumer Health 259 million R&D staff: 331 Integrated product pipeline for crop protection and seeds technology has combined peak sales potential of more than 5 billion from products launched Slide 8 Bayer Company Profile 2017

9 Pharmaceuticals Headquarters Berlin Number of employees* 38,110 Sales ,420 million Division Head Dieter Weinand * as of September 30, 2017 in full-time equivalents Folie 9 Bayer Company Profile 2017

10 Pharmaceuticals Division One of the leading innovative companies in the healthcare industry Largest division of Bayer in terms of sales Largest German pharma company & one of the fastest growing pharma companies worldwide Focus on prescription products, especially for cardiology, oncology, hematology, women s healthcare, and ophthalmology Radiology franchise with contrast-enhanced diagnostic imaging equipment and contrast agents Innovation is a cornerstone of our mission Science For A Better Life and a core element of our strategy. With our innovative solutions, we are responding to the global challenges in medical care. We are developing innovative treatments which offer added value compared to standard therapy, especially for diseases with a high medical need. Page 10 Pharmaceuticals Overview July 2017

11 Pharmaceuticals Business Areas Cardiovascular diseases Oncology Ophthalmology Women s health Hematology Radiology Other illnesses Multiple sclerosis Infections Diabetes Erectile dysfunction Testosterone deficiency Folie 11 Bayer Company Profile 2017

12 Pharmaceuticals Division Drug discovery activities focus on three therapeutic areas Cardiovascular Oncology Gynecology Heart Diseases Vascular Diseases Lung Diseases Kidney Diseases Hemostatic Disorders Acute Organ Disorders Oncogenic Signaling Antibody- Drug Conjugates Thorium Conjugates Immuno-Oncology Uterine Fibroids Endometriosis Polycystic Ovary Syndrome Cardiovascular Diseases and Oncology with a great potential for breakthrough impact on the lives of patients Leading R&D position in Gynecological Therapies Page 12 Pharmaceuticals Overview July 2017

13 Pharmaceuticals Division Additional focused research activities together with external partners Ophthalmology Hemophilia R&D of new delivery technologies for eye diseases Investigate the potential of Bayer s compounds together with the Johns Hopkins Wilmer Eye Institute Evaluate the CRISPR/Cas9 gene editing technology as new therapeutic approach together with Casebia, a Bayer/CRISPR Therapeutics JV Investigate and develop new therapeutic approaches for hemophilia Evaluate the potential of gene therapy for hemophilia patients together with Dimension Therapeutics Evaluate the CRISPR/Cas9 gene editing technology as new therapeutic approach together with Casebia, a Bayer/CRISPR Therapeutics JV Page 13 Pharmaceuticals Overview July 2017

14 Pharmaceuticals Division From Molecules To Medicine: The long process of drug development 1 Vorklinik Drug research Preclinical tests Clinical trials Approval 5 After launch From approx. 4million compounds, up to 10,000 are further tested and optimized More than 1 billion Euro < 250 Test compounds < 5 Test compounds 1 Drug Approved By Health Authorities Jahre All approved drugs Collecting and evaluating real-life data for ongoing benefit-risk assessment Page 14 Pharmaceuticals Overview July 2017

15 Pharmaceuticals Division Drug discovery sites around the globe Oncology Berlin Gynecology Cross-Indication Platform Clinical Sciences Oslo Oncology: Thorium Conjugates Platform Clinical Sciences Tokyo Clinical Sciences Berkeley San Francisco R&D of Biologics Whippany Clinical Sciences Wuppertal Cologne Cardiovascular Diseases R&D of Biologics Cross-Indication Platform Clinical Sciences Turku Polymer-based Drug Delivery Systems Beijing Clinical Sciences Osaka Clinical Sciences 7,934 employees in R&D in billion investment in R&D in %* investment in R&D of total net sales in 2016 Page 15 Pharmaceuticals Overview July 2017 *Fx adjusted

16 Pharmaceuticals Division Innovation Centers help to manage Bayer s global network of partnerships across indications Beijing Berlin CoLaborator Innovation Center China San Francisco West Coast Innovation Center CoLaborator Boston East Coast Innovation Center Osaka Innovation Center Japan Singapore Innovation Center Singapore Region Page 16 Pharmaceuticals Overview July 2017

17 Pharmaceuticals Division Our open innovation initiatives complement our innovation strategy Grants4Targets Bayer allocates grants for the exploration of attractive, novel drug targets and biomarkers. Grants4Apps Bayer funds projects for novel software, hardware or technologies contributing to improve health outcomes or pharmaceutical processes. In addition, the Grants4Apps Accelerator in Berlin supports 5 digital health startups each year. Grants4Indications Bayer promotes the exploration of new indications and offers grants and further financial support for promising proposals. PartnerYourAntibodies Bayer offers financial support to evaluate antibodies or derivates and to promote their exploration for a potential new drug development. CoLaborator Bayer offers attractive laboratory and office spaces for young life-sciences companies at its premises in Berlin and San Francisco. Consortia Bayer is engaged in multi-partner collaborations and large public-private-partnerships, e.g. Innovative Medicines Initiative, to foster innovation across industry and beyond. Page 17 Pharmaceuticals Overview July 2017

18 Disclaimer (1) Forward-Looking Statements Certain statements contained in this presentation may constitute forward-looking statements. Actual results could differ materially from those projected or forecast in the forward-looking statements. The factors that could cause actual results to differ materially include the following: uncertainties as to the timing of the transaction; the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in the merger within the expected time-frames or at all and to successfully integrate Monsanto s operations into those of Bayer; such integration may be more difficult, time-consuming or costly than expected; revenues following the transaction may be lower than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the announcement of the transaction; the retention of certain key employees at Monsanto; risks associated with the disruption of management s attention from ongoing business operations due to the transaction; (continued on slide 54) Slide 18 Bayer Company Profile 2017

19 Disclaimer (2) (continued from slide 53) Forward-Looking Statements the conditions to the completion of the transaction may not be satisfied, or the regulatory approvals required for the transaction may not be obtained on the terms expected or on the anticipated schedule; the parties ability to meet expectations regarding the timing, completion and accounting and tax treatments of the merger; the impact of the refinancing of the loans taken out for the transaction, the impact of indebtedness incurred by Bayer in connection with the transaction and the potential impact on the rating of indebtedness of Bayer; the effects of the business combination of Bayer and Monsanto, including the combined company s future financial condition, operating results, strategy and plans; other factors detailed in Monsanto s Annual Report on Form 10-K filed with the SEC for the fiscal year ended August 31, 2016 and Monsanto s other filings with the SEC, which are available at and on Monsanto s website at and other factors discussed in Bayer s public reports which are available on the Bayer website at Bayer and Monsanto assume no obligation to update the information in this communication, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date. (continued on slide 55) Slide 19 Bayer Company Profile 2017

20 Disclaimer (3) (continued from slide 54) Legal Notice The product names designated with are brands of the Bayer Group or our distribution partners and are registered trademarks in many countries. Slide 20 Bayer Company Profile 2017

21 Thank you for your attention!